JP3186880B2 - Hepatocyte isolation method - Google Patents

Hepatocyte isolation method

Info

Publication number
JP3186880B2
JP3186880B2 JP02907693A JP2907693A JP3186880B2 JP 3186880 B2 JP3186880 B2 JP 3186880B2 JP 02907693 A JP02907693 A JP 02907693A JP 2907693 A JP2907693 A JP 2907693A JP 3186880 B2 JP3186880 B2 JP 3186880B2
Authority
JP
Japan
Prior art keywords
liver
solution
preperfusion
collagenase
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP02907693A
Other languages
Japanese (ja)
Other versions
JPH06237763A (en
Inventor
滋章 平尾
良平 山本
豊和 西野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kurashiki Spinning Co Ltd
Original Assignee
Kurashiki Spinning Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurashiki Spinning Co Ltd filed Critical Kurashiki Spinning Co Ltd
Priority to JP02907693A priority Critical patent/JP3186880B2/en
Publication of JPH06237763A publication Critical patent/JPH06237763A/en
Application granted granted Critical
Publication of JP3186880B2 publication Critical patent/JP3186880B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は、動物(ヒトを除く、以
下同様)の肝細胞を分離する方法に関する。
The present invention relates to an animal (excluding humans)
The same as below) .

【0002】[0002]

【従来の技術】肝臓の持つ多種多様な特異機能の研究に
おいて、肝実質細胞の初代培養細胞を用いる手段が注目
されている。細胞培養のためには肝細胞を分離すること
がが必須である。
2. Description of the Related Art In the study of a variety of specific functions of the liver, attention has been paid to a means of using primary cultured cells of liver parenchymal cells. For cell culture, it is essential to separate hepatocytes.

【0003】肝細胞は主に、細胞間の金属イオンに依存
する接着因子と細胞間基質によって接着して肝臓を構成
している。肝細胞の分離法としてはコラゲナーゼのイン
・サイチュ灌流により細胞間基質の消化を行う方法が主
流である。この方法は、動物肝臓をまず緩衝液で前灌流
したのちにコラゲナーゼを灌流させ、肝細胞を穏やかに
分離させる方法である。前灌流時に金属イオン依存性の
接着因子を除くためにEGTA等を含む灌流液を用い、
化学的な分離を組み合わせることも行われている。
[0003] Hepatocytes are mainly composed of an adhesion factor which depends on a metal ion between cells and an intercellular matrix to constitute a liver. As a method for separating hepatocytes, a method of digesting an intercellular matrix by in situ perfusion of collagenase is mainly used. In this method, animal liver is first preperfused with a buffer solution, and then perfused with collagenase to gently separate hepatocytes. Using a perfusion solution containing EGTA etc. to remove metal ion-dependent adhesion factors during preperfusion,
Combinations of chemical separations have also been performed.

【0004】しかしながら、上記のごとき灌流法で肝細
胞を分離した場合、得られる細胞の生存率が一定せず、
高収率で安定な細胞の分離が困難である。これは分離細
胞を用いた実験の信頼性にも影響する。市販のコラゲナ
ーゼのロット差によるものであると考えられるが、その
原因は明らかでない。
However, when hepatocytes are separated by the perfusion method as described above, the survival rate of the obtained cells is not constant,
It is difficult to isolate cells with high yield and stability. This also affects the reliability of experiments using isolated cells. It is thought to be due to lot differences of commercially available collagenase, but the cause is not clear.

【0005】[0005]

【発明が解決しようとする課題】本発明は、生存率の高
い肝細胞を得るための肝細胞の分離方法を提供すること
を目的とする。
SUMMARY OF THE INVENTION An object of the present invention is to provide a method for separating hepatocytes to obtain hepatocytes having a high survival rate.

【0006】[0006]

【課題を解決するための手段】すなわち本発明は、少な
くともニンニク抽出物を含有する前灌流液を動物の肝臓
にイン・サイチュで灌流させたのち、さらにイン・サイ
チュでコラゲナーゼ液を灌流させて肝臓を消化すること
を特徴とする肝細胞の分離方法に関する。
That is, the present invention provides a method for perfusing a liver of an animal with a preperfusion solution containing at least a garlic extract in situ, and further perfusing a collagenase solution in situ with a liver solution. And a method for separating hepatocytes, characterized by digesting hepatic cells.

【0007】前灌流液の基本処方としては従来用いられ
ているもの、例えばラットの場合にはEGTA(エチレ
ングリコールビス(2−アミノエチルエーテル)四酢
酸)およびHEPESを添加し、カルシウムイオンとマ
グネシウムイオンを除いたハンクス緩衝液等が好適に用
いられるが、これに限定されるものではなく、動物の種
類等によって添加物の種類、濃度等は適宜選択すればよ
い。
[0007] As the basic prescription of the preperfusion solution, those conventionally used, for example, in the case of rats, EGTA (ethylene glycol bis (2-aminoethyl ether) tetraacetic acid) and HEPES are added, and calcium ions and magnesium ions are added. A Hanks buffer solution or the like excluding the above is preferably used, but the present invention is not limited to this, and the type and concentration of the additive may be appropriately selected depending on the type of the animal.

【0008】本発明においては、上記従来の前灌流液に
ニンニクの抽出物を添加する。ニンニクの抽出物は、ニ
ンニクを粉砕して水に浸漬して抽出したものを用いる。
また、前灌流液と同様のpHが4〜9の水溶液、例えば
緩衝液にて抽出してもよい。例えば水によって抽出する
場合にはニンニク20〜100gに対して1リットルの
水に浸漬し、室温で1時間抽出したものを用いればよ
い。
In the present invention, a garlic extract is added to the above-mentioned conventional preperfusion solution. The garlic extract is obtained by crushing garlic and immersing it in water.
Alternatively, extraction may be performed with an aqueous solution having a pH of 4 to 9 similar to that of the preperfusion solution, for example, a buffer solution. For example, when extracting with water, garlic may be immersed in 1 liter of water for 20 to 100 g and extracted at room temperature for 1 hour.

【0009】ニンニク抽出物の添加量は、その濃度にも
よるが、500mlの前還流液に対し、50ml程度ま
でが適当である。無菌的に細胞を得たい場合には前灌流
液に添加する前にフィルター滅菌をする必要がある。
The amount of garlic extract to be added depends on its concentration, but is suitably up to about 50 ml per 500 ml of pre-refluxed liquid. If cells are to be obtained aseptically, it is necessary to sterilize the filter before adding the cells to the preperfusate.

【0010】本発明の方法において、肝臓のイン・サイ
チュ灌流の手法は限定的ではなく、既知の方法を使用す
る動物に合わせて用いればよい。例えばラットの肝臓を
灌流する場合には、小平らの方法(実験医学第6巻第1
1号第1105頁〜1113頁(1988年))で行え
ばよい。すなわち、腹部を切開し、門脈からカニューレ
を挿入して灌流液を灌流させる。前灌流時には同時に下
大静脈を切断して脱血させる。その後心臓にもカニュー
レを挿入し、コラゲナーゼを含有する灌流液は循環させ
て用いる。灌流させる液体は、全て動物の体温程度に加
温するのが好ましい。
[0010] In the method of the present invention, the technique of in situ perfusion of the liver is not limited, and may be used in accordance with an animal using a known method. For example, when perfusing the liver of a rat, a small flat method (Experimental Medicine Vol.
No. 1, pages 1105 to 1113 (1988). That is, the abdomen is incised, a cannula is inserted from the portal vein, and the perfusate is perfused. At the time of preperfusion, the inferior vena cava is simultaneously cut and blood is removed. Thereafter, the heart is also cannulated, and the perfusate containing collagenase is circulated for use. It is preferable that all the liquid to be perfused is heated to about the body temperature of the animal.

【0011】前灌流により肝臓内の血液をすべて下大静
脈より脱血させ、さらにEGTAによってカルシウム依
存性の接着因子を除き、細胞を分離しやすくする。前灌
流は動物の種類、大きさによっても異なるが、例えば体
重150g程度のラットである場合には、1分間につき
30mlの流速で5分から15分行い、合計で100〜5
00mlの前灌流液を流す。前灌流が順調であれば肝臓は
一様に白くなる。
[0011] All blood in the liver is removed from the inferior vena cava by preperfusion, and calcium-dependent adhesion factors are removed by EGTA to facilitate cell separation. The preperfusion varies depending on the type and size of the animal. For example, in the case of a rat weighing about 150 g, the preperfusion is performed at a flow rate of 30 ml per minute for 5 to 15 minutes, for a total of 100 to 5 minutes.
Pour 00 ml of preperfusate. If the preperfusion is successful, the liver becomes evenly white.

【0012】前灌流の終了後、灌流液をコラゲナーゼ液
に変えて肝臓を酵素的に消化する。コラゲナーゼ液は、
従来使用されている処方のものを用いれば良い。現在、
主に使用されているのはハンクス液にトリプシンインヒ
ビターとカルシウムイオンを添加し、さらに0.05%
のコラゲナーゼを添加した溶液である。コラゲナーゼは
市販のものを用いればよいが、ロットによって多少活性
が異なるので適宜希釈して用いればよい。また、これに
チオールプロテアーゼ阻害剤やセリンプロテアーゼ阻害
剤などを配合してもよい。
After the end of preperfusion, the perfusate is changed to collagenase solution to enzymatically digest the liver. Collagenase solution
Conventionally used formulations may be used. Current,
It is mainly used by adding trypsin inhibitor and calcium ion to Hanks' solution and adding 0.05%
This is a solution to which collagenase was added. Commercially available collagenase may be used, but it may be appropriately diluted and used since its activity varies somewhat depending on the lot. Further, a thiol protease inhibitor, a serine protease inhibitor, or the like may be added thereto.

【0013】灌流は前灌流と同じ速度、すなわち体重1
50g程度のラットであれば毎分30mlで行う。灌流
を8〜15分間続け、コラゲナーゼによる消化が進む
と、肝臓は弾力を失いピンセットで軽く押しても元に戻
らなくなる。この時点で灌流を終了し、肝臓を取り出し
てシャーレに移す。コラゲナーゼによる消化が不十分で
あってもあるいは時間をかけすぎて消化が進み過ぎても
得られる細胞の生存率は低下する。
[0013] Perfusion is at the same rate as preperfusion, ie a weight of 1
For a rat weighing about 50 g, the test is performed at 30 ml per minute. As the perfusion is continued for 8 to 15 minutes and the digestion by collagenase progresses, the liver loses elasticity and cannot be returned to its original state even by lightly pressing with tweezers. At this point, the perfusion is terminated, the liver is removed and transferred to a petri dish. Insufficient collagenase digestion, or excessive digestion over time, results in reduced cell viability.

【0014】シャーレに移した肝臓の皮膜を切り裂く
と、肝細胞はとろけるように分離する。さらに氷冷した
細胞洗浄液を添加して先太の駒込ピペットで軽くピペッ
ティングすると大部分の肝細胞が単細胞として分離する
ので、これをガーゼ等で濾過した濾液を粗分散細胞浮遊
液とする。得られた粗細胞浮遊液は常套の方法で分離
し、必要に応じて精製して用いれば良い。
When the skin of the liver transferred to the petri dish is dissected, hepatocytes are separated so as to melt. Further, when an ice-cooled cell washing solution is added and most of the hepatocytes are separated as single cells by light pipetting with a thick Komagome pipette, the filtrate obtained by filtering with gauze or the like is used as a coarsely dispersed cell suspension. The obtained crude cell suspension may be separated by a conventional method, and purified and used if necessary.

【0015】本発明によれば肝実質細胞を、従来の方法
によるものと比べて高い生存率で安定して得ることがで
きる。また、実質細胞のみならず、常套法によりクッパ
ー細胞や内皮細胞等の非実質細胞を分取するのに本発明
の分離方法を用いることもできる。
According to the present invention, hepatic parenchymal cells can be stably obtained at a higher survival rate than those obtained by conventional methods. In addition, the separation method of the present invention can be used to collect not only parenchymal cells but also non-parenchymal cells such as Kupffer cells and endothelial cells by a conventional method.

【0016】本発明によって得られる肝実質細胞は、従
来の方法で培養するか、あるいはそのままで様々な試
験、研究に応用することができる。また試験、研究のみ
ならず、株化細胞とハイブリドーマを形成させ、有用物
質、例えばワクチン等の大量生産に用いたり、薬物の毒
性試験に用いたりすることも可能である。本発明の方法
は条件を選べばラットのみならず、マウス、モルモッ
ト、ウサギ、イヌ等他の動物の肝臓にも応用することが
できる。
The hepatic parenchymal cells obtained by the present invention can be cultured by a conventional method or can be applied to various tests and studies as they are. In addition to testing and research, it is possible to form a hybridoma with a cell line and use it for mass production of useful substances, for example, vaccines and the like, and for drug toxicity tests. The method of the present invention can be applied to not only rats but also livers of other animals such as mice, guinea pigs, rabbits, dogs, etc., if conditions are selected.

【0017】以下実施例により本発明をさらに詳細に説
明する。実施例は本発明の一例であり、本発明はこれに
限定されるものではない。
Hereinafter, the present invention will be described in more detail with reference to examples. The embodiment is an example of the present invention, and the present invention is not limited to the embodiment.

【0018】[0018]

【実施例】動物および試薬 実験は全てラット(雄性、ウィスター種、週令4〜7、
体重100〜250g)を用いて行った。実施例および
比較例は各3連で行った。基礎前灌流液およびコラゲナ
ーゼ溶液の組成を表1に示した。
EXAMPLES All animal and reagent experiments were performed on rats (male, Wistar, 4-7 weeks old).
Weight (100-250 g). Examples and comparative examples were performed in triplicate. Table 1 shows the compositions of the basal preperfusate and the collagenase solution.

【0019】[0019]

【表1】 [Table 1]

【0020】コラゲナーゼは和光純薬社製、トリプシン
インヒビターはシグマ社製のものを用いた。
The collagenase used was manufactured by Wako Pure Chemical Industries, Ltd., and the trypsin inhibitor used was manufactured by Sigma.

【0021】基礎前灌流液は全ての試薬を溶解し、Na
OHにてpH7.2に調整したものを用いた。コラゲナ
ーゼ溶液はコラゲナーゼ以外の試薬を溶解し、NaOH
でpH7.2〜7.4に調整した後、コラゲナーゼ粉末を
撹拌しながら少しずつ添加して溶解させ、さらに1時間
撹拌し、十分に溶解させた後pHを正確に7.5に調整
して濾過滅菌後100mlずつ分注して冷蔵保存したも
のを用いた。
The basal preperfusate dissolves all reagents and
The one adjusted to pH 7.2 with OH was used. The collagenase solution dissolves reagents other than collagenase,
After adjusting the pH to 7.2-7.4, the collagenase powder is added little by little with stirring to dissolve, and the mixture is further stirred for 1 hour. After sufficiently dissolving, the pH is adjusted to exactly 7.5. After sterilization by filtration, 100 ml was dispensed and stored refrigerated.

【0022】実施例1 ニンニク約65gを1リットルのイオン交換蒸留水中に
投入し、家庭用ミキサー(三洋電機社製)にかけて粉砕
した後、室温で約1時間撹拌した。12,000rpm
で遠心分離し、不純物を取り除き、上清をニンニク抽出
物とした。このニンニク抽出物50mlを上記基礎前灌
流液500mlに添加したものを実施例1の前灌流液と
した。
Example 1 About 65 g of garlic was put into 1 liter of ion-exchange distilled water, pulverized with a household mixer (manufactured by Sanyo Electric Co., Ltd.), and stirred at room temperature for about 1 hour. 12,000 rpm
The supernatant was used as a garlic extract. The garlic extract (50 ml) added to the basal preperfusion solution (500 ml) was used as the preperfusion solution of Example 1.

【0023】比較例 比較例としてはニンニク抽出物を添加しない基礎前灌流
液を用いて前灌流した。
Comparative Example As a comparative example, preperfusion was performed using a basal preperfusion solution to which no garlic extract was added.

【0024】イン・サイチュ灌流 灌流は、上記小平らの方法にて行った。ネンブタール液
で麻酔したラットを開腹し、門脈より、ペリスタリック
ポンプにセットした灌流用チューブの先端に付けたカニ
ューレを挿入して固定した。直ちに下大静脈を切断して
脱血させながら、38℃に加温した実施例および比較例
の前灌流液を、流速30ml/minにて灌流させた。前灌
流は10分間行った。
In situ perfusion Perfusion was performed by the small flat method described above. A rat anesthetized with Nembutal solution was opened, and a cannula attached to the tip of a perfusion tube set in a peristaltic pump was inserted and fixed from the portal vein. Immediately after the inferior vena cava was cut and blood was removed, the preperfused solution of Example and Comparative Example heated to 38 ° C. was perfused at a flow rate of 30 ml / min. Preperfusion was performed for 10 minutes.

【0025】灌流すると肝臓は一様に白く脱血される。
この間に胸腔を大きく切開し、心臓を露出させ、その後
肝臓下の下大静脈を鉗子で止め、ただちに右心房に入る
下大静脈にカニューレを挿入して固定した。前灌流終了
後後、ポンプを一旦止め、灌流液を38℃に加温したコ
ラゲナーゼ液に変えて同じ流速で灌流を行った。約1分
後、肝臓および灌流チューブから前灌流液が排出された
ら心臓より出て来る液をコラゲナーゼ液に戻してさらに
灌流を続けた。
When perfused, the liver is uniformly bleached white.
During this time, a large incision was made in the thoracic cavity to expose the heart, after which the inferior vena cava below the liver was stopped with forceps and the inferior vena cava immediately entering the right atrium was cannulated and fixed. After the end of the preperfusion, the pump was stopped once, and the perfusion was performed at the same flow rate by changing the perfusion solution to a collagenase solution heated to 38 ° C. After about 1 minute, when the preperfusion solution was drained from the liver and the perfusion tube, the solution coming out of the heart was returned to the collagenase solution, and the perfusion was further continued.

【0026】コラゲナーゼ液による灌流は約10分間続
け、肝臓が消化され、肝小葉が浮き上がったような外観
を呈し、表面の弾力がなくなりピンセットで軽く押して
も元に戻らなくなった時点で灌流を終了し、肝臓をピン
セットでつまみあげてハサミで切り離し、氷上に保持し
たシャーレに移した。
The perfusion with the collagenase solution was continued for about 10 minutes, and the perfusion was terminated when the liver was digested and the hepatic lobules appeared as if they had risen, and the surface was not elastic enough to return to the original state even when pressed gently with forceps. The liver was picked up with tweezers, cut off with scissors, and transferred to a Petri dish kept on ice.

【0027】シャーレに移した肝臓はメスで肝臓皮膜を
切り裂き、氷冷MEM(動物細胞培養用基礎培地(大日
本製薬社製))を20ml添加し、先太の駒込ピペット
にてゆっくりとピペッティングして十分に分散させた。
この細胞分散液を二重にしたガーゼを通した後濾液を4
本のガラス製スピッツ型遠沈管に移しMEMで1本当た
り40mlとして先太の駒込ピペットで分散させた後冷
却下で50×g、1分間で遠心分離した。この条件では
無傷の肝実質細胞がパックされ、損傷肝細胞、非実質細
胞、赤血球および細胞の破片は上清に残る。上清を除
き、新たにMEMを添加してピペッティングを行い、同
様の遠心分離を繰り返す。このようにして、細胞を集め
ながら4回遠心分離を行った。最終的に96〜98%の
純度で肝実質細胞を得ることができた。
The liver transferred to the petri dish was cut through the liver capsule with a scalpel, and 20 ml of ice-cold MEM (basic culture medium for animal cell culture (manufactured by Dainippon Pharmaceutical Co., Ltd.)) was added, followed by slow pipetting with a thick Komagome pipette. And fully dispersed.
This cell dispersion was passed through a double gauze, and the filtrate was filtered for 4 hours.
The mixture was transferred to a glass Spitz-type centrifuge tube, made to be 40 ml per tube with MEM, dispersed with a thick Komagome pipette, and then centrifuged under cooling at 50 × g for 1 minute. Under these conditions, intact hepatocytes are packed and damaged hepatocytes, non-parenchymal cells, red blood cells and cell debris remain in the supernatant. The supernatant is removed, MEM is newly added, pipetting is performed, and the same centrifugation is repeated. Thus, centrifugation was performed four times while collecting the cells. Finally, hepatocytes could be obtained with a purity of 96 to 98%.

【0028】最終的に1個の肝臓当たり40mlのME
Mに懸濁した細胞懸濁液とし、その一部を取ってこれに
0.3%のトリパンブルーを添加した後に軽く混合して
生細胞および死細胞数を血球計算板を用いて計数し、生
存率を計算した。死細胞は、トリパンブルーによって青
く染色される。
Finally, 40 ml of ME per liver
M, aliquots were taken, 0.3% trypan blue was added thereto, mixed gently, and the number of live and dead cells was counted using a hemocytometer. Survival was calculated. Dead cells are stained blue by trypan blue.

【0029】得られた肝実質細胞の生存率は、比較例が
79±3.1%であったのに対して、実施例1の水によ
り抽出されたニンニク抽出物を前灌流液に添加したもの
では85±2.4%であった(n=3)。
The survival rate of the obtained hepatocytes was 79 ± 3.1% in the comparative example, whereas the garlic extract extracted with water in Example 1 was added to the preperfusate. It was 85 ± 2.4% (n = 3).

【0030】[0030]

【発明の効果】本発明の方法で分離した肝細胞は生存率
が高く、収率が一定している。
The hepatocytes isolated by the method of the present invention have a high survival rate and a constant yield.

───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) C12N 5/00 - 5/28 BIOSIS(DIALOG) WPI(DIALOG)────────────────────────────────────────────────── ─── Continued on the front page (58) Fields surveyed (Int. Cl. 7 , DB name) C12N 5/00-5/28 BIOSIS (DIALOG) WPI (DIALOG)

Claims (2)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 少なくともニンニク抽出物を含有する前
灌流液を動物(ヒトを除く)の肝臓にイン・サイチュで
灌流させたのち、さらにイン・サイチュでコラゲナーゼ
液を灌流させて肝臓を消化することを特徴とする肝細胞
の分離方法。
1. A method of perfusing a liver of an animal (excluding a human) with a preperfusion solution containing at least a garlic extract in situ, and further perfusing a collagenase solution in situ to digest the liver. A method for separating hepatocytes, characterized in that:
【請求項2】 動物がラットである請求項1記載の肝細
胞の分離方法。
2. The method according to claim 1, wherein the animal is a rat.
JP02907693A 1993-02-18 1993-02-18 Hepatocyte isolation method Expired - Fee Related JP3186880B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP02907693A JP3186880B2 (en) 1993-02-18 1993-02-18 Hepatocyte isolation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02907693A JP3186880B2 (en) 1993-02-18 1993-02-18 Hepatocyte isolation method

Publications (2)

Publication Number Publication Date
JPH06237763A JPH06237763A (en) 1994-08-30
JP3186880B2 true JP3186880B2 (en) 2001-07-11

Family

ID=12266262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP02907693A Expired - Fee Related JP3186880B2 (en) 1993-02-18 1993-02-18 Hepatocyte isolation method

Country Status (1)

Country Link
JP (1) JP3186880B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101861776B1 (en) * 2017-11-07 2018-07-05 상진에이알피(주) Assembly type stacking rack

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110106140A (en) * 2019-06-03 2019-08-09 华中农业大学 A kind of separation method of mouse portal vein week liver cell and central vein week liver cell

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101861776B1 (en) * 2017-11-07 2018-07-05 상진에이알피(주) Assembly type stacking rack

Also Published As

Publication number Publication date
JPH06237763A (en) 1994-08-30

Similar Documents

Publication Publication Date Title
US7547546B2 (en) Progenitor cells from wharton's jelly of human umbilical cord
Mellgren et al. The renal subcapsular site offers better growth conditions for transplanted mouse pancreatic islet cells than the liver or spleen
WO2019161591A1 (en) Isolation and cultivation method for mesenchymal stem cells, as well as cryopreservation and resuscitation method for same
US10329533B2 (en) Regenerative cell and adipose-derived stem cell processing system and method
CN109234229B (en) Method for separating mesenchymal stem cells from placental blood vessels and digestive enzyme composition used in same
EP1181524A2 (en) Method for enriching or depleting tumour cells obtained from a body fluid and kit suitable for this purpose
US20200360445A1 (en) Acellular biologic composition and method of manufacture
Smith et al. Studies of the metabolism of separated bone cells: I. Techniques of separation and identification
CN106614524B (en) Preservation solution and preservation method for mesenchymal stem cells
CN110317781B (en) Method for freezing and resuscitating mesenchymal stem cells
CN110317782B (en) Method for improving survival of mesenchymal stem cells after resuscitation and frozen stock solution used by method
JP3186880B2 (en) Hepatocyte isolation method
CN108728408B (en) Canine fetal membrane mesenchymal stem cell, preparation method and culture medium used by same
JP3186881B2 (en) Hepatocyte isolation method
JPS603829B2 (en) Cell culture method
JP3862085B2 (en) Preservation method of microorganisms and animal-derived materials
TWI640625B (en) Method for rapid mincing of adipose tissues to isolate alive cells in vitro
EP3385368A1 (en) Method for producing mesenchymal stem cells
US20170095593A1 (en) Adipose-derived stem cell product
Potter et al. Sebaceous gland differentiation I. Separation, morphology and lipogenesis of isolated cells from the mouse preputial gland tumor
CN112011504A (en) Preparation method of placenta decidua mesenchymal stem cells
SE413131B (en) PROCEDURE FOR SEPARATION OF Lymphocytes FROM HELBLOOD
Xu et al. Function of a new internal bioartificial liver: an in vitro study
Holdsworth et al. Tissue culture of isolated human glomeruli
US20120142104A1 (en) Supplement for cell cultivation media

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees